FDA starts probe in­to a clin­i­cal tri­al death as next-gen CAR-T re­searchers stop en­roll­ment

Push­ing the en­ve­lope on next-gen CAR-T drugs, re­searchers run­ning an ear­ly-stage tri­al on a 2.0-style can­cer ther­a­py at Memo­r­i­al Sloan Ket­ter­ing Can­cer Cen­ter have hit the red light on en­roll­ment for now as they probe the re­cent death of a mesothe­lioma pa­tient. The tri­al pause cen­ters on a drug ad­vanced by Atara Bio­ther­a­peu­tics, which struck a $670 mil­lion col­lab­o­ra­tion deal on two mesothe­lioma projects — in­clud­ing this one — with Bay­er at the end of 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER